{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:04:30Z","timestamp":1790924670677,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["2021-A-11"],"award-info":[{"award-number":["2021-A-11"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s12185-024-03895-w","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T08:53:00Z","timestamp":1734339180000},"page":"378-387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system: HM-screen-JAPAN02"],"prefix":"10.1007","volume":"121","author":[{"given":"Hironori","family":"Arai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Hosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SungGi","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Iyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikashi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goichi","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-0739","authenticated-orcid":false,"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"issue":"21","key":"3895_CR1","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1182\/blood.2022015853","volume":"140","author":"EJ Duncavage","year":"2022","unstructured":"Duncavage EJ, et al. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022;140(21):2228\u201347.","journal-title":"Blood"},{"key":"3895_CR2","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research N et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374.","DOI":"10.1056\/NEJMoa1301689"},{"issue":"12","key":"3895_CR3","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","volume":"26","author":"A Burd","year":"2020","unstructured":"Burd A, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020;26(12):1852\u20138.","journal-title":"Nat Med"},{"issue":"5","key":"3895_CR4","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1111\/cas.15746","volume":"114","author":"N Hosono","year":"2023","unstructured":"Hosono N, et al. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. Cancer Sci. 2023;114(5):2098\u2013108.","journal-title":"Cancer Sci"},{"issue":"22","key":"3895_CR5","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1182\/blood.2020007626","volume":"137","author":"LK Schmalbrock","year":"2021","unstructured":"Schmalbrock LK, et al. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021;137(22):3093\u2013104.","journal-title":"Blood"},{"issue":"1","key":"3895_CR6","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12935-024-03368-4","volume":"24","author":"N Kim","year":"2024","unstructured":"Kim N, et al. Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomes. Cancer Cell Int. 2024;24(1):174.","journal-title":"Cancer Cell Int"},{"issue":"6","key":"3895_CR7","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","volume":"130","author":"MD Amatangelo","year":"2017","unstructured":"Amatangelo MD, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130(6):732\u201341.","journal-title":"Blood"},{"issue":"8","key":"3895_CR8","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","volume":"9","author":"CM McMahon","year":"2019","unstructured":"McMahon CM, et al. Clonal Selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019;9(8):1050\u201363.","journal-title":"Cancer Discov"},{"issue":"23","key":"3895_CR9","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"9","key":"3895_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367\u201376.","journal-title":"Blood"},{"issue":"9","key":"3895_CR11","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1182\/bloodadvances.2019001349","volume":"4","author":"C Gardin","year":"2020","unstructured":"Gardin C, et al. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Adv. 2020;4(9):1942\u20139.","journal-title":"Blood Adv"},{"issue":"17","key":"3895_CR12","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1182\/bloodadvances.2021004556","volume":"5","author":"I van der Werf","year":"2021","unstructured":"van der Werf I, et al. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification. Blood Adv. 2021;5(17):3254\u201365.","journal-title":"Blood Adv"},{"issue":"19","key":"3895_CR13","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood.2020010603","volume":"138","author":"H Awada","year":"2021","unstructured":"Awada H, et al. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. Blood. 2021;138(19):1885\u201395.","journal-title":"Blood"},{"issue":"9","key":"3895_CR14","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/ng.3371","volume":"47","author":"VP Lavallee","year":"2015","unstructured":"Lavallee VP, et al. The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. Nat Genet. 2015;47(9):1030\u20137.","journal-title":"Nat Genet"},{"issue":"12","key":"3895_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"20","key":"3895_CR16","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"4","key":"3895_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"9","key":"3895_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","volume":"18","author":"H Dohner","year":"2021","unstructured":"Dohner H, Wei AH, Lowenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol. 2021;18(9):577\u201390.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"3895_CR19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1182\/blood.2020007732","volume":"137","author":"GL Uy","year":"2021","unstructured":"Uy GL, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137(6):751\u201362.","journal-title":"Blood"},{"issue":"22","key":"3895_CR20","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1182\/blood.2020009759","volume":"137","author":"M Wermke","year":"2021","unstructured":"Wermke M, et al. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML. Blood. 2021;137(22):3145\u20138.","journal-title":"Blood"},{"issue":"14","key":"3895_CR21","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1182\/blood-2012-09-454553","volume":"121","author":"S Bertoli","year":"2013","unstructured":"Bertoli S, et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood. 2013;121(14):2618\u201326.","journal-title":"Blood"},{"issue":"7","key":"3895_CR22","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood.2019004583","volume":"136","author":"C Rollig","year":"2020","unstructured":"Rollig C, et al. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood. 2020;136(7):823\u201330.","journal-title":"Blood"},{"issue":"1","key":"3895_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2008-05-157065","volume":"113","author":"MA Sekeres","year":"2009","unstructured":"Sekeres MA, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009;113(1):28\u201336.","journal-title":"Blood"},{"issue":"6","key":"3895_CR24","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-021-01230-4","volume":"35","author":"RB Walter","year":"2021","unstructured":"Walter RB, et al. Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. Leukemia. 2021;35(6):1529\u201338.","journal-title":"Leukemia"},{"issue":"26","key":"3895_CR25","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party. Blood. 2021;138(26):2753\u201367.","journal-title":"Blood"},{"issue":"13","key":"3895_CR26","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189\u201399.","journal-title":"N Engl J Med"},{"issue":"8","key":"3895_CR27","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jama.2015.9643","volume":"314","author":"JM Klco","year":"2015","unstructured":"Klco JM, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314(8):811\u201322.","journal-title":"JAMA"},{"issue":"6","key":"3895_CR28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1603847","volume":"375","author":"M Othus","year":"2016","unstructured":"Othus M, Estey E, Gale RP. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;375(6): e9.","journal-title":"N Engl J Med"},{"issue":"3","key":"3895_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1182\/blood-2016-01-636381","volume":"128","author":"S Ogawa","year":"2016","unstructured":"Ogawa S. Clonal hematopoiesis in acquired aplastic anemia. Blood. 2016;128(3):337\u201347.","journal-title":"Blood"},{"issue":"2","key":"3895_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1200\/JCO.21.02286","volume":"40","author":"CJ Gibson","year":"2022","unstructured":"Gibson CJ, et al. Donor clonal hematopoiesis and recipient outcomes after transplantation. J Clin Oncol. 2022;40(2):189\u2013201.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3895_CR31","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.cell.2017.01.021","volume":"168","author":"DH Spencer","year":"2017","unstructured":"Spencer DH, et al. CpG island hypermethylation mediated by DNMT3A is a consequence of AML progression. Cell. 2017;168(5):801\u201316.","journal-title":"Cell"},{"issue":"4","key":"3895_CR32","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1182\/blood-2017-08-801985","volume":"131","author":"J Xia","year":"2018","unstructured":"Xia J, et al. Somatic mutations and clonal hematopoiesis in congenital neutropenia. Blood. 2018;131(4):408\u201316.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03895-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03895-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03895-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T12:42:48Z","timestamp":1740487368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03895-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3895"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03895-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"20 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.H.: Abbvie; Honoraria. T.Y.: Chugai: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Astellas: Honoraria, Research Funding; Nihon Shinyaku: Honoraria, Research Funding; Sumitomo Pharma: Honoraria, Research Funding; Janssen Pharma: Honoraria, Research Funding; Nihon Kayaku: Honoraria, Research Funding. K.F.: Janssen: Honoraria. S.I.: Alexion Pharmaceuticals: Honoraria, Research Funding; MSD: Research Funding; Otsuka Pharmaceutical: Honoraria, Research Funding; Sanofi: Honoraria, Research Funding; SymBio Pharmaceuticals: Honoraria, Research Funding; Astellas: Honoraria; CSL Behring: Honoraria; Daiichi Sankyo: Honoraria; Meiji Pharma: Honoraria; Nippon; Shinyaku: Honoraria; Novartis: Honoraria. A.G.: Nihon Pharmaceutical: Honoraria; Bristol Myers Squibb: Honoraria; Taiho Pharmaceutical: Honoraria, Research Funding; Sumitomo Pharma: Honoraria, Research Funding; Janssen Pharmaceutical: Honoraria; Chugai Pharmaceuticals: Consultancy, Honoraria, Research Funding; Asahi Kasei Pharma: Research Funding; Kyowa Kirin: Honoraria; Takeda Pharmaceutical: Honoraria; Daiichi Sankyo: Honoraria, Research Funding; Ono Pharmaceutical: Honoraria, Research Funding; AstraZeneca: Honoraria; Abbvie: Honoraria; Alexion Pharmaceuticals: Consultancy, Honoraria; Novartis: Honoraria; Pfizer Japan: Honoraria; Otsuka Pharmaceutical: Honoraria, Research Funding; Nippon Shinyaku: Honoraria; Sanofi: Honoraria; PharmaEssentia Japan: Consultancy, Honoraria. T.I.: Asahi Kasei Pharma, Nippon Shinyaku Co. Ltd: Research Funding; Bristol-Myers Squibb Company, Novartis Pharma KK, Pfizer Japan Inc., Takeda: Honoraria. C.Y.: Novartis Pharmaceuticals: Honoraria; Bristol Myers Squibb: Research Funding. G.Y.: AbbVie: Honoraria; astellas: Honoraria; Daiichi Sankyo Company, Limited: Honoraria; Amgen inc.: Honoraria. J.K.: Amgen: Ended employment in the past 24\u00a0months, Honoraria; Janssen Pharmaceutical K.K.: Honoraria; Novartis Pharma K.K.: Honoraria; Sanofi K.K.: Honoraria; AbbVie Pharma: Honoraria; Megakaryon Co.: Honoraria; Eisai Co.: Research Funding. N.T.: Astellas pharma: Other: Commissioned research and joint research, Research Funding; Asahi Kasei: Research Funding; Pfizer: Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding, Speakers Bureau; Otsuka Pharmaceutical: Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding, Speakers Bureau; Mochida Pharma: Research Funding; Novartis: Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding, Speakers Bureau. E.S.: Takeda: Speakers Bureau; Kyowa-Kirin: Research Funding; Chugai: Research Funding; Human Life Cord Japan: Consultancy; Ohara: Consultancy; Otsuka: Consultancy; Pfizer: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Janssen: Speakers Bureau. K.U.: Takeda: Research Funding; Nippon Shinyaku: Research Funding; SymBio: Research Funding; Alexion: Research Funding; Amgen: Research Funding; Sanofi: Research Funding; Alnylam Japan: Research Funding; Sando: Research Funding; Astellas: Research Funding; Otsuka: Research Funding; Eisai: Research Funding; Ohara: Research Funding; Chugai: Research Funding; Kyowa-Kirin: Research Funding. Y.M.: Daiichi Sankyo: Honoraria, Research Funding; Taiho Pharmaceutical: Research Funding; Tejin Pharma: Research Funding; Takeda: Research Funding; Sumitomo Pharma Oncology: Research Funding; Shionogi: Research Funding; Sanofi: Research Funding; Otsuka: Research Funding; Nippon Shinyaku: Research Funding; Nihonkayaku: Research Funding; Kyowa Hakko Kirin: Research Funding; Dainippon Sumitomo Pharma: Research Funding; Asahi Kasei: Research Funding; Taiho Pharmaceutical: Honoraria; Shinogi: Honoraria; Sanofi: Honoraria; Otsuka: Honoraria; Ono Pharmaceutical: Honoraria; Merck: Honoraria; Meiji Seika Kaisha: Honoraria; Lilly: Honoraria, Research Funding; Kyowa Hakko Kirin: Honoraria; Eisai: Honoraria, Research Funding; Chugai Pharma: Honoraria, Research Funding; Bayer: Honoraria, Research Funding; Abbvie: Honoraria; Pfizer Japan Inc.: Honoraria; Bristol-Myers Squibb Company: Honoraria; Takeda: Honoraria; Novartis Pharma KK: Honoraria. Takayuki Ikezoe and Emiko Sakaida are editors of International Journal of Hematology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was approved by the institutional review board at each center and carried out in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}